To keep price control to a minimum, the government can act in two areas where it has not done so far.
The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment into India.
Drug major Ranbaxy Laboratories on Thursday said it plans to launch more generic products in the US market with possible marketing exclusivity, while keeping options open for overseas acquisitions to grow its business in various global markets.
Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga
With West Bengal Chief Minister Mamata Banerjee seeking a uniform vaccination policy for the country, Union Health Minister Harsh Vardhan on Friday assured her that the Modi government was firm in its resolve to help the state fight the COVID-19 pandemic, but also flagged more than 40 per cent positivity rate in some districts of the state.
India's largest listed pharmaceutical (pharma) company - Sun Pharmaceutical Industries (Sun Pharma) - is expected to maintain its outperformance vis--vis the sector's, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages. While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent. Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma's minus 1.4 per cent.
Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time.
This is the sixth of seven ships built under 'Project 17 Alpha' for the Navy. The first five ships of the project were launched between 2019 and 2022.
National Pharmaceutical Pricing Authority names Cipla, Dr Reddy's Labs and Ranbaxy among those.
The long-pending issue of seizure of Indian generic drugs by European Union countries has been resolved, with the EU accepting India's position and agreeing to amend the rules to plug the loopholes that led to the seizure of shipments.
A new agreement has been clinched with pharmaceutical firms to substantially decrease the cost of treating AIDS in 66 countries in Asia, Latin America, Africa and the Caribbean, former US President Bill Clinton has announced.
The Serum Institute of India (SII) had put in an application to the Drugs Controller General of India (DCGI) in October for grant of market authorisation of Covovax for restricted use in emergency situations.
The company has received final approval from the US Food and Drug Administration for its Abacavir Sulfate Lamivudine, and Zidovudine Tablets, Lupin Ltd said in a statement.
Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.
Ranbaxy Laboratories edged higher on Tuesday following reports that the company has received the regulators nod to market a new drug in the US.
The company has received the tentative approval from the US Food & Drug Administration to manufacture and market these combination tablets in strengths of 600mg/300mg/ 300mg, a statement by Aurobindo Pharma said.
Drug makers join the chyawanprash bandwagon with sugar-free variants.
A joint venture of Synbiotics, a wholly owned subsidiary of Ambalal Sarabhai Enterprises (ASE), and CoDiagnostics, CoSara Diagnostics is the first and only Indian company so far to receive a licence from the Central Drugs Standard Control Organisation (CDSCO) to manufacture coronavirus diagnostic test kits.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US.
The Enforcement Directorate, probing the case, has claimed Yusuf had assisted Mirchi in buying properties in India using money earned through illegal activities.
.jpg)
The company's US subsidiary, Lupin Pharmaceuticals Inc has launched its Ciprofloxacin for oral suspension in the US market in the strengths of 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL), Lupin said in a statement.
The termination of the MoU came after the deal with the Brazilian government for supply of 20 million doses of the vaccine landed in controversy and attracted investigation by authorities in that country.
Garcetti suggested that the two countries are working on certain agreements to bolster defence cooperation and they are likely to be firmed up when Modi visits the US or President Joe Biden comes to India in September for the G20 summit.
At the Leo fete, Vijay had this also to tell his fans: 'I know you all are in my heart. But today, I also know that I am also in the hearts of all of you...' A typical politician's line, did you say, asks N Sathiya Moorthy.
Once touted as a 'wonder drug', HCQ has been battling global controversies around its safety and efficacy as a prophylactic against the new coronavirus SARS-CoV-2.
Baba Ramdev drug sample had human parts: Govt\n
As many as 150 applications are stuck at evaluation stage, says official.
The Pune-based firm had submitted interim safety and immunogenicity data of phase 2/3 bridging clinical trial conducted in the country as well as interim clinical trial data of safety and efficacy from phase3 clinical trials conducted in the UK and the US along with its application.
"If we are able to get all the shares of Taro Pharmaceuticals, including promoters shares, then the total cost would be up to Rs 1,000 crore," Sun Pharmaceutical Industries chairman Dilip Shanghvi said at conference call on Sunday.
Drug maker Cipla always fought a lone battle to make drugs affordable in India.
The Rs 3,290 crore (Rs 32.9 billion) Sun plans to sell Topamax in four strengths ranging from 25mg to 200mg, the combined market for which is estimated to be $2.5 billion. There is, of course, no litigation with the patent holder OrthoMcneill Janssen. The US market, which brings in about 40 per cent of Sun's consolidated sales and has driven revenues in the past few year could lose momentum.
Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting.Adverse event following immunisation will continue to be monitored.
China has asked Olympic-bound athletes and coaches to sign a pledge not to use banned drugs and pass a written test, as it seeks to enforce its zero-tolerance stance on doping, Xinhua news agency reported on Thursday.
The PhRMA's observation is significant against the backdrop of Swiss pharma major Novartis AG's decision to relocate its R&D investments from India.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances